Clinical

Dataset Information

0

Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modalities


ABSTRACT: Positron Emission Tomography (PET scanning) is performed using a total dose of less than 50 mRad per patient visit. Fludeoxyglucose F 18 (FDG) is injected intravenously over 2 min. Initial dynamic images will be obtained over the heart. Emission imaging will work from the midcervical region down to the perineal region. For CEA scanning, radiolabeled antibody, arcitumomab (IMMU-4), is injected intravenously over 5 min. A single photon emission computed tomography (SPECT) transmission scan is performed over the same regions as the emission scans. Total dose from transmission scans should be no more than 20 mRad per patient visit. Patients then undergo exploratory laparotomy performed by two surgeons, one blinded to the results of the CEA-Scan and PET scan. At the completion of all exploration, all identified disease is biopsied for pathologic analysis and any resectable disease is removed. Patients are followed every 3 months for 1 year, every 6 months for the second year, and then after 3 years.

DISEASE(S): Colorectal Neoplasm,Colorectal Neoplasms

PROVIDER: 2001364 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2016-06-09 | MTBLS233 | MetaboLights
2010-03-22 | GSE19493 | GEO
2019-08-19 | GSE130215 | GEO
2019-08-19 | GSE130214 | GEO
2019-08-19 | GSE130213 | GEO
2019-08-19 | GSE134543 | GEO
2019-08-19 | GSE130224 | GEO
2019-08-19 | GSE130216 | GEO
| 2237035 | ecrin-mdr-crc
2004-02-09 | GSE852 | GEO